Pfizer
Pfizer could have first oral drug for COVID-19 by end of year: CEO Bourla
Washington/Sputnik: Pfizer’s experimental oral drug to treat COVID-19 at the first sign of illness could be available before the end of the year, Chief Executive Albert Bourla told CNBC on Tuesday.
The drug is part of a class of medicines called protease inhibitors and works by inhibiting an enzyme that the virus needs to replicate in human cells, Bourla told the network in an interview. If clinical trials go well and the Food and Drug Administration approves it, the drug could be distributed across the United States by the end of the year, he added.
Pfizer, which developed with German drugmaker BioNTech the first COVID-19 vaccine approved by US health authorities last year, began in March this year an early stage clinical trial that deployed protease inhibitors used for treating viral pathogens such as HIV and hepatitis C, Bourla said.
CNBC quoted health experts as saying the oral drug could be a game changer because people newly infected with the virus could use it outside of hospitals. Researchers hope the new medication will keep the disease from progressing and prevent hospital trips.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
